Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Linagliptin

A list of these Linagliptin articles makes it easy for you to quickly access relevant information. We have prepared the following professional Linagliptin, hoping to help solve your questions and better understand the product information you care about.
  • Drug Patent & Exclusivity Expiration Report - Week of April 28 2025

    Drug Patent & Exclusivity Expiration Report - Week of April 28 2025

    2025-04-28

    This week, there are 16 drugs in the patent and exclusivity list. They are: - PF PRISM CV's INLYTA, containing active ingredient AXITINIB - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - IPSEN BIOPHARMACEUTICALS INC's ONIVYDE, containing active ingredient IRINOTECAN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM's GLYXAMBI, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRIJARDY XR, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRADJENTA, containing active ingredient LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO XR, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Read More